There were quite a lot of shares traded today (c230k) after a very slow start this morning.
Needs some momentum now if we are to be back in the FTSE250 on the 22nd at close of play. It's possible - just a question of how likely.
Last Friday £551m market cap would have nudged out 325th place. OXB have roughly 106m shares so 520p per share needed in 13 trading days for that assuming the value of the index stays the same.
418p at close today so +8p per day on average might be enough. You know I have hopes that getting back into the MSCI this week will bring in the buyers to do that - but I'm not sure. |
Chart looks good to me as a novice. Could be fireworks tonight? |
The Eurovision side of this always makes me smile. Anyway, back to OXB.
OXB presented recently in Rome at the European Society of Cell & Gene Therapy 2024 conference.
You'd never guess unless you looked for it, but the relevant poster they presented is hidden on the OXB website here
Crucial part to note here for those of us interested in OXB are the terms SAN & M-SAN.
"Our findings demonstrate that the use of SAN and M-SAN exhibited superior activity under typical LV manufacturing conditions.".
SAN is Salt Active Nucleases and it's the technology of ArcticZymes where our CEO Frank is the new Chairman and I understand from today's internet trawl that OXB are the first to try it.
”M-SAN demonstrated superior performance compared to the Industry Standard Nuclease when integrated into OXB’s LV production process”
"SAN also outperformed the Industry Standard Nuclease when integrated into OXB’s LV production”
“Over 10-fold reduction in residual DNA compared to the Industry Standard Nuclease” |
Good to see a valued partner progressing Marcus, but just to clarify BEAM-201 is the CAR-T we partner them with. |
John Evans
@john_evans3
·
1h
In the liver, we have also completed dosing of the first cohort for the BEAM-302 trial for AATD, and have sites opening around the world.
Startup is progressing well for BEAM-301 in GSD1a in the US.
In a few hours we will also share the abstracts/data submitted to ASH and accepted for the conference, as well as holding a conference call at 8:30am ET where we will discuss the results |
Oh dear ..this is how religious wars start. |
I would have thought Psalm 22 was more appropriate here. |
Even though I walk through the valley of the shadow of death, I fear no evil, for You are with me; Your rod and Your staff, they comfort me.
Psalm 23
Well,well,i think a bit of scripture reading wouldn’t go amiss in the Dominic household.Thereagain,could be a reference to “into the valley of death rode the 600’.Time will tell. |
Mainly heathens on the BBs Gareth. You may have to explain that. |
23rd Psalm, a Psalm of David? |
 Many have made points in the past here about the number of shares firmly held these days and the decreasing fraction available to churn with the usual changes in supply and demand. I'm sure those aren't quite the correct terms, but as the likes of Blackrock (perhaps a bad example) appear holding 5% or more then what happens when news or some other event creates a sudden demand?
You know I'm a bull, never hide it and there are a few others on the thread of a similar mind who have been here for a very long time. So yes there will be confirmation bias but I'm convinced OXB was way oversold because most small shareholders who bought in for covid only knew OXB as a covid share and when the vaccine work ended they all charged for the door and created a death spiral.
How much that was helped by people in dark glasses who saw the opportunity to make a lot of money out of it I don't know, but as I have pointed out before with links to the shares shorted chart which I post occasionally, when most shares are outstanding the threads here are being carpet-bombed with very negative posts by a handful of people. Once the shorts closed then it stopped. OK some of them may just have been idiots entertaining themselves, but a remarkable coincidence if no connection to most of it.
I have a hindsight feeling that OXB + much better PR could have just about kept that at bay had not Homology gone bump, but that's fortunes of war. With hindsight it would have been better had we never seen them, but at the time the smart money said go AAV. You know what happened next.
But here we are having travelled through the shadow of the valley of death, and still with a chance this month of having all past sins forgiven via readmission to the MSCI and FTSE250. Not long to find out with the first one there. |
All the buzz words there ‘operational gearing’,̵7;excellent growth prospects’ and even a mention of being a potential tasty corporate morsel for good measure.Yes,once Oxford Biomedica becomes profitable,its probably fair to assume that Threadneedle (under whatever guise) will be buying more.Makes me wonder how many other sizeable institutions have this unwritten rule that they don’t buy lossmakers.All of a sudden,the OXB boat could be on a broad reach with the wind in its sails once it becomes profitable and one will regret not buying more despite the memorably choppy ride. |
I'm going to go into OXB OCD again here SJ, but the following may be of interest:-
A long time ago there was a "financial TV" type interview with one of the fund managers from Threadneedle posted on here.
Apart from the Novartis / Pfizer slip obviously a lot more knowledgeable than the interviewer about OXB - i.e. a follower and if you look at the last annual report on page 116 then they were buyers already this year - i.e. 3,183,728 at the beginning of the year and 3,245,381 by 15th of April.
I may be hearing what I want to hear in the interview, but it sounds very much to me that he's implying they will be in for more as OXB turns profitable - which as we know is the year which is 8 weeks away.
I'm sure he knows that better than us. I'd also bet another pound of Dom's money that the Threadneedle guy will know if OXB is going to be back in the MSCI this week or not. |
Columbia Threadneedle Management Limited is wholly owned by Columbia Threadneedle Holdings Limited, which is wholly owned by Columbia Threadneedle Group (Management) Limited, which is wholly owned by Columbia Threadneedle Group (Holdings) Limited, which is wholly owned by Columbia Threadneedle AM (Holdings) Plc, which is wholly owned by Columbia Threadneedle (Europe) Limited, which is wholly owned by Columbia Threadneedle Investments UK International Limited, which is wholly owned by Ameriprise Financial, Inc.which which which |
Well,i'll take it as reassuring without going too deeply into the rather opaque world of holding declarations.There can be an unsatisfactory delay between time of dealing and notification of a share holding and i would guess that this share purchase was the reason why the shares shot from 390 to around 440 in short order the week before last.It could be the large buyer which Dominic C understood was in the wings a fortnight back. |
No great surprise that low, and better than the techmark index I suppose :) |
Well spotted Cousin.
takeiteasy,
Have you seen the fraction of healthcare in the MSCI? (page 2 pie chart) |
So Columbia Threadneedle (per the RNS detail) were down as 3.06% in the OXB annual report, so have built another 2% over the last 6 months or so. Their business also now includes the old F&C/I&S/BMO funds but not sure where the OXB position held. |
Ameriprise Financial, Inc. is an American diversified financial services company and bank holding company based in Minneapolis, Minnesota.[1] It provides financial planning products and services, including wealth management, asset management, insurance, annuities, and estate planning.[1]As of April 2022, more than 80% of the company's revenue came from wealth management.[1][2]Ameriprise was formerly a division of American Express, which completed the corporate spin-off of the company in September 2005.The company is ranked 245th on the Fortune 500.[3] It is on the list of largest banks in the United States. and was also ranked the 9th largest independent broker-dealer based on assets under management. It is one of the largest financial planning companies in the United States and is among the 25 largest asset managers in the world.[1] It is ranked 8th in long-term mutual fund assets in the U.S., fourth in retail funds in the U.K., and 27th in global assets under management |
Honestly never heard of them Tricky, but
(quote)
The company specializes in retirement-related financial planning for affluent clients. It offers variable annuities and life and disability insurance. It also operates Ameriprise Bank, FSB, which offers a variety of consumer banking and lending products and personal trust and related services. Since 2015, its asset management arm has operated under the name Columbia Threadneedle Investments. The company uses three principal brands for its businesses in the United States: Ameriprise Financial, Columbia Management and RiverSource.
(unquote)
We have seen Threadneedle before I think so maybe a bit of a tangled web here? |
So our accumulator is unveiled. |
Not impossible - interesting just how few firms from the health sector are linked to FTSE 250...look at the big investors in this area e.g. Mercantile IT close to zero investment in this sector and as you look at all the other names it follows a very similar pattern.
We need firms like OXB to build a strong and stable franchise that develops some level of dull and boring predictability that the institutional investors would be looking for using their so called " data screens" based on investment output stats on risk and return and market cap data.
This share seems so thinly traded that it takes a small puff of wind to more the dial up thank goodness near term so we do not need a huge push from bigger IIs but do hope later into 2025 that all the IR push we are making towards this cohort starts to show up a bit more.
Getting back over 430 today may bring back the momentum crowd...wdik.. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
